Impact of Gamma-OH on Sleep in ICU Patients

Poitiers University Hospital20 enrolled

Overview

The Main objective of the trial is to assess sleep quality with Gamma-OH® in patients difficult to wean from mechanical ventilation in the ICU.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Weaning from Mechanical Ventilation

Interventions

Gamma HydroxybutyrateDRUG

Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * intubated at least 24 hours * difficult weaning from mechanical ventilation according to international guidelines, i.e. who failed at least one spontaneous breathing trial. * Patients will be included after to obtain inform consent. Exclusion Criteria: * neuromuscular disease * central nervous disease * psychiatric disease * severe obesity

Locations (1)

CHU Poitiers

Poitiers, Poitiers, France

Outcomes

Primary Outcomes

Proportion of patients having poor sleep with Gamma-OH

Primary end point will be analyzed from sleep recordings performed during a single night with Gamma-OH®.

Time frame: Hour24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.